Table 2

Characteristics of studies examining the external validity of the Framingham Anderson and Wilson risk scores

Location, reference, date	Name of study	Specific inclusions	Men	Age (years)	Start date of recruitment	Follow up (years)	Outcomes	Study type
BRHS, British Regional Heart Study; CHD, coronary heart disease; CVD, cardiovascular disease; HT, hypertension; INSIGHT, Intervention as a Goal in Hypertension Treatment; LIFE, Losartan Intervention For Endpoint reduction in hypertension study; LVH, left ventricular hypertrophy; PRIME, Prospective Epidemiological Study of Myocardial Infarction; PROCAM, Prospective Cardiovascular Munster; RCT, randomised controlled trial; WHO MONICA, World Health Organization Multinational Monitoring of Trends and Determinants in Cardiovascular Disease; WOSCOPS, West of Scotland Coronary Prevention Study.
Framingham Anderson
Europe, Bastuji-Garin et al¹⁷ 2002	INSIGHT	All patients taking HT drugs	45%	55–74	1994	3.7	CHD, CVD	RCT hypertension intervention and control groups
Augsburg, Germany, men, Hense et al¹³ 2003	WHO MONICA Augsburg	Men	100%	35–64	1984	10.5	CHD	Community
Augsburg, Germany, women, Hense et al¹³ 2003	WHO MONICA Augsburg	Women	0%	35–64	1984	10.5	CHD	Community
Munster, Germany, men, Hense et al¹³ 2003	PROCAM	Men	100%	35–64	1979	11.6	CHD	Occupational
Munster, Germany, women, Hense et al¹³ 2003	PROCAM	Women	0%	35–64	1979	11.1	CHD	Occupational
N Europe/USA, Kjeldsen et al¹⁸ 2000	LIFE	Essential HT and ECG-LVH	46% (overall in study)	55–80	1995	1	CVD	RCT hypertension intervention and control groups
New Zealand, men, Milne et al¹⁹ 2003	Fletcher-Challenge–University of Auckland Heart and Health Study	Men	100%	35–74	1992	5	CVD	Community and occupational
New Zealand, women, Milne et al¹⁹ 2003	Fletcher-Challenge–University of Auckland Heart and Health Study	Women	0%	35–74	1992	5	CVD	Community and occupational
Scotland, WOSCOPS control, WOSCOPS Group²⁰ 1998	WOSCOPS	Moderate hypercholesterolaemia (control)	100%	45–64	1989	4.4	CVD	RCT lipid-lowering control group
Scotland, WOSCOPS pravastatin, WOSCOPS Group²⁰ 1998	WOSCOPS	Moderate hypercholesterolaemia (pravastatin)	100%	45–64	1989	4.4	CVD	RCT lipid-lowering intervention group
UK, Brindle et al²¹ 2003	BRHS		100%	40–59	1978	10	CHD	Community
UK, Caerphilly & Speedwell 1, Brindle et al²² 2004	Caerphilly and Speedwell Studies	1979–1983	100%	45–63	1979	10	CHD	Community
UK, Caerphilly & Speedwell 2, Brindle et al²² 2004	Caerphilly and Speedwell Studies	1982–1988	100%	47–67	1982	10	CHD	Community
UK, diabetic men, McEwan et al¹⁴ 2004	Cardiff Diabetes Database	Men with new diabetes diagnosis	100%	30–74	1996	4	CHD	Patients with diabetes
UK, diabetic women, McEwan et al¹⁴ 2004	Cardiff Diabetes Database	Women with new diabetes diagnosis	0%	30–74	1996	4	CHD	Patients with diabetes
UK, diabetics, Guzder et al²³ 2002	Poole	New diabetes diagnosis	57%	30–74	1996	4.2	CVD	Patients with diabetes
UK, Whickham, Ramachandran et al¹⁶ 2000	Whickham Study		44%	30–75	1972	20	CHD	Community
USA, Orford et al²⁴ 2002	Normative Aging Study, Boston	Health check volunteers	100%	30–74	1961	10	CHD	Health check volunteers
Framingham Wilson
Australia, men, Simons et al²⁵ 2003	Dubbo Study, Australia	Men	100%	60–79	1988	10	CVD	Community
Australia, women, Simons et al²⁵ 2003	Dubbo Study, Australia	Women	0%	60–79	1988	10	CVD	Community
France, Empana et al²⁶ 2003	PRIME, France		100%	50–59	1991	5	CHD	Occupational
Germany, angiography, Schulz et al²⁷ 2003		Patients with CHD negative coronary angiography	100%	Mean 53	1992	10	MI	Angiography patients
Northern Ireland, Empana et al²⁶ 2003	PRIME, Belfast		100%	50–59	1991	5	CHD	Community and occupational
USA, Johns Hopkins, siblings 1, Blumenthal et al¹² 2003	Johns Hopkins Sibling Study	Family history of premature CHD	64%	Mean 46		10	CHD	CVD family history
USA, Johns Hopkins, siblings 2, Becker et al¹⁵ 2001	Johns Hopkins Sibling Study	Family history of premature CHD	52%	30–59	1983	10	CHD	CVD family history
USA, Los Angeles, Greenland et al²⁸ 2004	South Bay Heart Watch, Los Angeles	High risk	90%	>45	1990	7	CHD	High risk